131 results about "Pharmacologic action" patented technology

A computer-implemented system for personalized health optimization constructs a confidence-weighted personal health knowledge graph (PHKG) from heterogeneous data, including wearable sensors, medical devices, lab results, medication logs, and conversational inputs. A multi-stage causal-inference stack identifies modifiable drivers of outcomes using layered methods (e.g., MI, GAM, Neural Granger, DAG-GNN), and simulates candidate interventions. A recommendation engine ranks lifestyle or pharmacologic actions using a benefit-to-friction score, selecting a personalized intervention aligned with user readiness and clinical safety constraints. Interventions may include a minimum effective dose (MED), optimal level, adaptive low-dose, or behavioral challenge. Optional modules include reinforcement learning for timing adaptation and privacy-preserving on-device inference. The system operates across domains including metabolic, cardiovascular, renal, sleep, stress, and medication response, enabling cross-condition synergy evaluation. The architecture is modular, supports runtime plug-in targets, and adapts in real time with or without continuous clinical oversight, depending on deployment.

The invention relates to the technical field of test optimization, in particular to a biomedical test optimization system based on a graphic model, which comprises a data collection module, a graphic weight adjustment module, a path exploration module and an optimization adjustment module. According to the method, the drug concentration and the reaction data of the biomarker are synchronously integrated through real-time data, the whole test process can be covered, real-time updating and accurate mapping of the data can be ensured, the reliability and effectiveness of the test are greatly enhanced, and the dynamic data can be obtained through updating the weights of nodes and edges in a graphic model in real time. The model can accurately reflect the actual interaction effect between drugs, path analysis and pharmacological action relation marking are carried out by utilizing updated data, the pertinence and scientificity of the test are further enhanced, key variables and action paths can be quickly identified, a drug combination scheme is optimized, the research and development efficiency and cost control are remarkably improved, and the research and development efficiency is improved. The research and development period of the medicine is greatly shortened.

The invention discloses a phloretin derivative and application thereof in preparation of a medicine for treating diabetes, relates to the technical field of medicines, and in particular relates to a compound as shown in a formula (1) and alpha-glucosidase inhibitory activity of the compound. Pharmacological experiment results show that the compound shown in the formula (1) has extremely high alpha-glucosidase inhibitory activity, so that the generation of glucose is inhibited, and the pharmacological action of resisting diabetes mellitus is exerted through the action mechanism.

The invention discloses a BimBH3 analogue containing D-type amino acid and N-terminal fatty acid acylation, a preparation method of the BimBH3 analogue and application of the BimBH3 analogue as a PTPN1 inhibitor to development of hypoglycemic drugs. The structural general formula of the novel BimBH3 mimic peptide analogue is shown as a formula I: # imgabs0 #, wherein Raa2 is equal to D-His, D-Leu, D-Pro, D-Ser, D-Arg, D-Gln, D-Lys, D-Trp, D-Val, D-Tyr, D-Ala, Raa3 is equal to D-Gln, Raa7 is equal to D-Arg, and Raa8 is equal to D-Allo-Ile. The mimic peptide compound is derived from a core region of a Bim-BH3 structural domain, different D-type amino acid site-specific replacement modification and N-terminal conjugated hexadecanoic acid modification are adopted for amino acids at the second, third, seventh and eighth sites respectively, the BimBH3 mimic peptide modified by the D-type amino acid is more stable and has higher metabolic stability, and the target binding capacity and inhibitory activity of the BimBH3 mimic peptide can still be reserved or even improved. The BimBH3 mimic peptide compound shows an excellent PTPN1 inhibitor, the ability of resisting protease hydrolase and various digestive enzymes is also remarkably improved, and the BimBH3 mimic peptide compound has longer pharmacological action time and can play a potential long-acting hypoglycemic role through subcutaneous injection or oral administration. The compound is completely prepared by a polypeptide solid-phase synthesis method, and an obtained crude product is subjected to semi-preparative liquid chromatography purification and freeze-drying to obtain a target compound.

The invention discloses a novel application of hydroxytyrosol or 3, 4-dihydroxyphenethyl alcohol-O-beta-D-glucoside in promotion of melanogenesis, and relates to a preparation method of hydroxytyrosol or 3, 4-dihydroxyphenethyl alcohol. Hydroxytyrosol is a phenolic plant chemical substance, has good pharmacological effects in the aspects of microorganism resistance, inflammation resistance, tumor resistance, oxidation resistance, cardiovascular disease and metabolic syndrome treatment, detoxification and the like, and is widely applied to various fields. The pharmacological action of hydroxytyrosol or 3, 4-dihydroxyphenethyl alcohol-O-beta-D-glucoside in promoting melanogenesis is verified by analyzing the melanogenesis condition of hydroxytyrosol or 3, 4-dihydroxyphenethyl alcohol-O-beta-D-glucoside on recombinant human tyrosinase, mouse B16 cells and wild zebra fish melanin of AB strains. The invention finds that the hydroxytyrosol or the 3, 4-dihydroxyphenylethanol-O-beta-D-glucoside can obviously promote the generation of melanin, a new thought can be provided for blackening, treating hypopigmentation diseases, blackening hair and the like by utilizing the new biological activity of the hydroxytyrosol or the 3, 4-dihydroxyphenylethanol-O-beta-D-glucoside, and the new medical application of the hydroxytyrosol or the 3, 4-dihydroxyphenylethanol-O-beta-D-glucoside is expanded.

The present invention relates to a crystal form of a bipyrimidine compound and a preparation method therefor and a use thereof. In particular, the present invention relates to a crystal form I of 4'-cyclopropyl-5,6'-dimethoxy-N-((4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)bicyclic[2.2.2]oct-1-yl)methyl)-[2,5'-bipyrimidine]-4-amine, and the X-ray powder diffraction pattern of the crystal form I comprises characteristic peaks at diffraction angles (2θ) of 6.378±0.2°, 9.521±0.2°, 15.721±0.2°, 16.379±0.2°, 16.981±0.2°, 17.560±0.2°, 19.080±0.2°, and 22.200±0.2°. The crystal form I has high stability, high solubility, high plasma concentration, high bioavailability, and excellent pharmacological action, and is therefore suitable for pharmaceutical preparations.

The invention discloses application of gentiopicroside in preparation of a medicine for improving liver fatty degeneration and ferroptosis of type 2 diabetes mellitus, and belongs to the technical field of medicines. A C57BL / 6J mouse T2DM model induced by combination of high-fat feed and streptozotocin is taken as a research object, gentiopicroside is given for 8 weeks through oral administration and intragastric administration, metabolic indexes such as blood sugar, body weight, food intake and water intake of the mouse are dynamically monitored, serum and liver tissue are reserved after the mouse is killed, and the mouse can be used for preparing the gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside. Through liver pathological staining, serum and liver tissue oxidative stress index detection and PI3K / AKT / Nrf2 signal channel and ferroptosis related protein expression analysis, the pharmacological action of the gentiopicroside on T2DM is systematically evaluated, the regulation effect of the gentiopicroside on T2DM liver fatty degeneration and ferroptosis is determined for the first time, the research blank of the action mechanism of the gentiopicroside in T2DM liver complications is filled, and the application prospect of the gentiopicroside in T2DM liver complications is broadened. An experimental basis is provided for developing a novel medicine for improving T2DM liver fatty degeneration and ferroptosis.

The invention relates to the technical field of traditional Chinese medicine formula matching, in particular to a traditional Chinese medicine formula intelligent matching system which comprises a data acquisition module, a data processing module, a model training module and a prescription matching module. The data acquisition module is used for acquiring medicinal material and formula information from traditional Chinese medicine literatures, a medical database, experimental research results and clinical cases through a data interface and a crawler technology, and storing the medicinal material and formula information into a unified database; the data processing module is used for performing structured processing on the acquired unstructured text data by adopting an NLP technology and extracting names, indications, doses, pharmacological actions and incompatibility of the medicinal materials; the model training module is used for carrying out classification and correlation analysis on the prescription combination based on a machine learning algorithm and generating model parameters for prescription matching; according to the prescription matching module, a user can perform retrieval according to various screening conditions such as a purpose, a dosage form, an action mechanism and a region, and a system screens a prescription combination which most accords with the conditions from a database according to a matching algorithm and a training model.

The invention belongs to the fields of biotechnology and information technology, and relates to a method for a biological medicine compound to act on a pulmonary fibrosis target spot caused by inflammation, in particular to a construction method for analyzing the pulmonary fibrosis target spot caused by the effect of a phellinus igniarius medicinal component on the inflammation. According to the method, a network model of phellinus igniarius active ingredients and pulmonary fibrosis related biomarkers is constructed through network pharmacology, pharmacological actions and potential targets of the active ingredients are predicted by utilizing a machine learning algorithm, and the core ingredients of phellinus igniarius for relieving pulmonary fibrosis are obtained by utilizing a molecular docking method. The toxicity of the phellinus igniarius and the inhibition effect of the phellinus igniarius on secretion of inflammatory factors are verified by utilizing an in-vitro cell experiment, so that efficient screening of active ingredients of the phellinus igniarius and deep analysis of an action mechanism are realized. Through the method, the efficiency and accuracy of medicine screening can be improved, and a scientific basis is provided for application of the phellinus igniarius active ingredients in the aspect of treating pulmonary fibrosis.

This invention relates to the application of oridonin in the preparation of agents that improve muscle function, specifically by improving skeletal muscle dysfunction, enhancing insulin sensitivity, promoting myoblast differentiation into myotube cells, and / or increasing myoblast insulin sensitivity. Using an in vitro C2C12 myoblast model, this invention demonstrates that oridonin can promote myoblast differentiation and growth and increase C2C12 myoblast insulin sensitivity. Through an obesity-induced skeletal muscle dysfunction model, it is demonstrated that oridonin can improve skeletal muscle dysfunction and insulin resistance by increasing muscle strength, muscle endurance, muscle mass, and reducing muscle lipid accumulation. This invention provides new insights for drug research on improving skeletal muscle dysfunction and enhancing insulin sensitivity, and also enriches the pharmacological system of oridonin.

The invention belongs to the technical field of organic synthesis. The invention particularly relates to a synthesis method of chiral beta-diaryl ethanol. The physiological activity, the pharmacological action and the material performance of the chiral molecule are directly determined by the spatial configuration of the chiral molecule. Therefore, efficient construction of chiral compounds is always the core research direction of organic synthesis and medicinal chemistry. Wherein the chiral beta-diaryl ethanol is a kind of key intermediates with irreplaceable application value. According to the invention, the Suzuki-Miyaura type asymmetric ring-opening coupling reaction of nickel catalyzed aryl epoxy and aryl boric acid with high stereoselectivity is realized, and the asymmetric ring-opening coupling reaction is used for synthesizing chiral beta-diaryl alcohol compounds. The method is wide in substrate compatibility and raw material source, mild in reaction condition, free of exogenous alkali and convenient to operate. An aryl epoxy compound and arylboronic acid are used as raw materials, diethylene glycol dimethyl ether nickel bromide is used as a catalyst, chiral biimidazoline is used as a ligand, under the promotion of sodium iodide, reaction is performed in an ethanol solvent according to the following reaction formula at the temperature of 50 DEG C for 10 hours, and the chiral beta-diaryl ethanol compound with the high ee value is obtained.

The invention discloses a hypnotic traditional Chinese medicine pillow based on traditional Chinese medicine theory and ergonomics and a traditional Chinese medicine formula in the pillow, and particularly relates to the technical field of hypnotic traditional Chinese medicine pillows.The hypnotic traditional Chinese medicine pillow comprises a pillow inner body and detachable medicine bags, the detachable medicine bags are symmetrically arranged on the left side and the right side of the pillow inner body, and the detachable medicine bags are filled with traditional Chinese medicine mixtures; the traditional Chinese medicine mixture is prepared from the following raw materials in parts by weight: 1 part of rhizoma atractylodis, 1 part of rhizoma acori graminei, 0.5 part of radix angelicae, 1 part of wormwood, 1 part of rhizoma cyperi and 0.2 part of rhizoma kaempferiae. The components complement and cooperate in pharmacological action to jointly enhance the effects of tranquilizing and allaying excitement and improving sleep, the sleeping effect is improved in cooperation with a specific micronization treatment and low-temperature crushing process, and the traditional Chinese medicine sleeping effect is improved through deep integration of the traditional Chinese medicine sleeping theory, ergonomic design and a modern preparation process. The nerve soothing effect of traditional Chinese medicine and cervical vertebra comfortable supporting form a superimposed effect, and multi-dimensional upgrading from a single sleeping function to stable medicine effect, comfortable use and convenient maintenance is achieved.

The invention provides a bio-based high-viscosity gel plaster matrix, a preparation method of the bio-based high-viscosity gel plaster matrix and a patch containing a simvastatin component. The matrix is prepared from various natural components including dementholized peppermint oil serving as an aromatic, crotamiton and isopropyl myristate serving as penetration promoting agents, glycerin serving as a humectant, a specific cross-linking agent, a filling agent, an excipient, a tackifier and the like through accurate proportioning and a specific process. The composition has excellent adhesion, moisture retention and skin friendliness. Particularly, the tackifier adopts a compound formula of xanthan gum, Arabic gum, guar gum and flaxseed gum, so that the adhesion, the stability and the transdermal effect of the plaster are further improved. On the basis, the invention further provides a patch containing a simvastatin component, the patch is prepared by uniformly mixing simvastatin in a matrix and has a treatment effect, the pharmacological action of simvastatin is exerted, and the use comfort and effect are improved.

The invention belongs to the technical field of drug detection, and particularly relates to a method for detecting lycium barbarum glycopeptide metabolites in rat plasma and tissues based on non-targeted metabonomics. According to the method, after rat lycium barbarum glycopeptides are administered through intragastric administration, blood, liver, intestine, lung and brain tissue samples after administration are collected. A UPLC-Q-TOF-MS (Ultra Performance Liquid Chromatography-Quadrupole Time of Flight Mass Spectrometry) analysis method is combined with a statistical analysis method comprising principal component analysis (PCA) and orthogonal-partial least squares discriminant analysis (OPLS-DA) to carry out in-vivo metabonomics analysis on the wolfberry glycopeptide. Then, based on a human metabolome database (HMDB), lycium barbarum glycopeptide differential metabolite is searched, so that the pharmacological action mechanism of the lycium barbarum glycopeptide is clarified from the perspective of metabolism, and a foundation is laid for deep research and development of the medicinal value of the lycium barbarum glycopeptide in future.

The invention relates to a polymorphic form of an endopiroxostat addition salt as well as a preparation method and application of the polymorphic form. The acid addition salt is selected from the group consisting of hydrochloride, sulfate, phosphate, mesylate, benzene sulfonate, p-toluenesulfonate, hydrobromide, maleate, tartrate, citrate and fumarate, preferably hydrochloride. The endopiroxostat addition salt polymorph is high in stability, high in solubility, high in blood concentration, high in bioavailability and excellent in pharmacological action, so that the endopiroxostat addition salt is suitable for pharmaceutical preparations.

Pharmacological, sanitary, or dietary preparation for use in the treatment of low salivary secretion, which includes any Withania somnifera (ashwagandha) plant extract, obtained by means of any method and at any concentration. The use of the Withania somnifera (ashwagandha) plant is intended for the treatment of low salivary secretion by the pharmacological action of the extract from any part of the plant.

The invention relates to the field of biological medicine, in particular to vortioxetine and application of pharmaceutically acceptable salts, solvates, crystal forms and prodrugs of vortioxetine to preparation of drugs for preventing or treating pathogenic fungal infection. The application reveals that the antidepressant vortioxetine (vortioxetine) and hydrobromide thereof (vortioxetine. HBr) which are sold on the market have measurable in-vitro inhibitory activity on various clinical common pathogenic fungi for the first time, so that the pharmacological action spectrum of the compound is expanded, and a new candidate direction is provided for research and development of antifungal drugs; the application not only overcomes the defects of existing antifungal drugs in the aspects of drug resistance, biological membranes and safety, but also opens up a brand new application direction of mental small molecule drugs in the anti-infection field, and has remarkable technical innovation, social value and industrial popularization prospect. The application also provides a theoretical basis for establishing a'multi-modal micromolecular antifungal library ', and can promote the development of pharmacological mechanism research and fungal infection precise treatment.

Provided herein are pharmaceutical formulations comprising glucokinase activator, or a prodrug, or a pharmaceutically acceptable salt, an isotope labeled analogue, a crystalline form, a hydrate, a solvate, or a diastereomeric or enantiomeric form thereof and the use thereof for treating diseases; the pharmaceutical formulations are in the form of immediate-release formulations, extended-release formulations, or combination of immediate-release formulation and extended-release formulations. The pharmaceutical formulations achieved once-a-day therapy for some diseases, in particular, type II Diabetes Mellitus with obesity. The pharmaceutical formulations exhibit sustained 24 hours of glucose-lowering effects. The pharmaceutical formulations also achieved lower Cmax, extended T1 / 2 as well as maintained similar bioavailability and increased MRT compared with commercial Dorzagliatin tablet, enhanced the pharmacology effect of restoring the glucose stimulated GLP-1 secretion in diabetes with obesity.

The application discloses application of a Fructus Mume pill in preparation of a medicine for treating diabetic encephalopathy, and finds that there is a clear correlation between the Fructus Mume pill and the diabetic encephalopathy. Research results show that the Fructus Mume pill can improve the abnormal metabolic state of a diabetic model mouse, reduce learning and memory dysfunction and cognitive impairment under a diabetic state, and has a good prevention and treatment effect on the diabetic encephalopathy. The application clearly defines the pharmacological effect of the Fructus Mume pill in preventing and treating the diabetic encephalopathy and a possible action mechanism, and provides an experimental basis for TCM intervention on the diabetic encephalopathy. The application provides a new train of thought for research and development of a medicine related to the diabetic encephalopathy, and has a good application prospect.

The present invention provides diazo compounds having anti-trypanosomal activity, with less or no side-effects. The diazo compounds are structural analogue of quinapyramine and possess characteristics necessary for the targeted pharmacologic action of anti trypanosomosis, with reduced cytotoxicity. The compounds were found to have less cytotoxicity, and identical or better anti- parasitemia effect as compared to conventional quinapyramine sulfate.

The invention belongs to the technical field of medicines, and discloses a gastrodia elata microbial fermentation product as well as a preparation method and application thereof. According to the invention, three aspergillus oryzae are utilized to successfully carry out microbial fermentation on gastrodia elata, the gastrodia elata microbial fermentation product of which the content of active ingredients gastrodin and p-hydroxybenzyl alcohol is obviously increased is obtained, and the pharmacological action of the gastrodia elata microbial fermentation product on treating or improving oligoasthenospermia is verified through an oligoasthenospermia mouse model; results show that the gastrodia elata microbial fermentation product has better effects of improving sperm concentration, enhancing sperm motility and rapidly moving forwards, can be used as an active ingredient of a medicine for treating or improving oligospermia and asthenospermia, and has wide application.

The invention belongs to the technical field of analysis and detection, and particularly relates to a method for simultaneously detecting chlorogenic acid, ferulic acid, dracorhodin, cinnamaldehyde, ligustilide and osthole in a rhizoma dioscoreae blood-activating patch. According to the invention, a'quantitative analysis of multi-components by single marker 'method is adopted, effective components in monarch drugs of radix angelicae pubescentis and ligusticum wallichii and ministerial drugs of dragon's blood and cinnamon in the rhizoma cyperi blood-activating patch are taken as indexes, cinnamaldehyde with clear pharmacological action and high content is taken as an internal standard, and calculation is carried out through relative correction factors between the other five to-be-detected compounds and cinnamaldehyde; the content of chlorogenic acid, ferulic acid, dracorhodin, cinnamaldehyde, ligustilide and cnidium lactone in the rhizoma gastrodiae blood-activating patch is obtained by detecting the content of cinnamaldehyde in the rhizoma gastrodiae blood-activating patch, so that the content of chlorogenic acid, ferulic acid, dracorhodin, cinnamaldehyde, ligustilide and cnidium lactone in the rhizoma gastrodiae blood-activating patch can be detected at the same time only by detecting the content of cinnamaldehyde in the rhizoma gastrodiae blood-activating patch; the aim of objectively, comprehensively and accurately performing quantitative control on the rhizoma cyperi blood-activating patch is achieved.

The present invention provides a phloretin derivative and its use in preparing a medicament for treating diabetes, relating to the field of medical technology, and particularly to a compound represented by formula (1) and its α-glucosidase inhibitory activity. Pharmacological experimental results show that the compound represented by formula (1) has extremely high α-glucosidase inhibitory activity, thereby inhibiting the production of glucose, and further exerting an anti-diabetic pharmacological effect through this mechanism of action.

The invention provides a traditional Chinese medicine composition for treating children atopic dermatitis and a preparation method thereof, and relates to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition comprises the following raw materials: 4-8 parts of rhizoma atractylodis, 6-10 parts of honeysuckle, 4-8 parts of cortex phellodendri, 4-8 parts of semen coicis, 4-8 parts of radix achyranthis bidentatae, 2-8 parts of radix sophorae flavescentis, 4-8 parts of cortex dictamni, 4-8 parts of fructus kochiae, 2-8 parts of cicada slough and The preparation method comprises the following steps: soaking the traditional Chinese medicinal materials in water, heating, refluxing, extracting, filtering and taking filtrate; concentrating the filtrate into clear paste, cooling, adding ethanol, standing, taking supernate, recovering ethanol, performing secondary concentration to obtain traditional Chinese medicine ointment, and granulating the traditional Chinese medicine ointment. The traditional Chinese medicine and modern pharmacological actions are combined to achieve the effects of clearing heat, eliminating dampness, tonifying spleen, excreting dampness, dispelling wind and arresting itching; in practical application, the traditional Chinese medicine composition has obvious improvement and cure conditions on children atopic dermatitis symptoms, and has the advantages of quick response, short curative effect, low side effect and no relapse after healing.

The invention belongs to the technical field of organic synthesis, focuses on innovation of a preparation method of an organic germanium compound, and particularly provides a novel photochemical synthesis path of an alpha-germanium oxime compound. According to the method, germane hydride, olefin and tert-butyl nitrite are taken as starting raw materials, and under the condition that no photocatalyst is added, only an ultraviolet light source is utilized for irradiation, so that the germanium-based / oximido-based bifunctionalization reaction of olefin is successfully realized for the first time. The method has the advantages of environmental friendliness, mild conditions, simplicity and convenience in operation, high atom economy, wide substrate application range and the like. The method can be used for modifying the drug molecule derivative after germanium group / oximidation, opens up a way for constructing an organic germanium compound with potential biological activity and pharmacological action, and is expected to play an important role in the field of medicine research and development.

The invention discloses an anti-fibrosis active ingredient high-throughput screening method based on a liver organ chip and application of the anti-fibrosis active ingredient high-throughput screening method. The invention provides a liver organ chip combined with a pore plate. The liver organ chip is used for high-throughput screening of anti-fibrosis active ingredients. The method specifically comprises the steps of building a high-throughput organ-like chip, forming a 3D fibrosis liver organ and screening the biological activity of an anti-fibrosis drug. According to the invention, the physiological state of the human liver is reproduced in an in-vitro culture environment by utilizing the principles of stem cell development and engineering, and the pharmacological action of the liver tissue on the medicines obeticholic acid and semeglutide under the pathological state of the human liver is remodeled; the method has great application value in the aspects of in-vitro organ simulation, high-throughput screening of drug efficacy and exploration of a response mechanism of an organism to a drug, and the construction mode of combining with a commercial pore plate is extremely simple, convenient, expansible and practical.

The application discloses a kind of based on graph neural network's pharmacological action target point prediction method of atractylin, comprising the following steps: S1. generating atractylin molecular structure standardization dataset;S2. the atractylin molecular structure standardization dataset is converted into molecular graph dataset;S3. constructing drug target point graph dataset;S4. based on graph neural network constructs atractylin pharmacological action target point prediction model;S5. using atractylin pharmacological action target point prediction model to the molecular graph dataset and interactive graph dataset are handled, output the interaction matching result between atractylin and each candidate target point, and determine potential pharmacological action target point according to matching result.The application can dynamically weight the characteristics of molecular atomic level and the characteristics of target point key amino acid residues, so that the prediction model can more accurately depict the local interaction characteristics of drug and target point.

The invention discloses berberine salt, belongs to the technical field of medical preparations, and particularly relates to berberine dialkyl acid salt (also called dialkyl acid salt berberine) which specifically comprises dibutyrate berberine and diacetate berberine. Compared with monoalkyl acid salt berberine, the dialkyl acid salt berberine has different chemical properties and physical properties; the quality is controllable, no difference exists between batches, and the stability is good; the dialkyl acid salt berberine has a better effect on improving the metabolic function and inhibiting tumor cell proliferation, and the pharmacological action is enhanced.

The present application belongs to the technical field of pharmaceutical preparations, more specifically to the technical field of cardiovascular disease therapeutic drugs, and particularly relates to a new use of fibrinogen for preparing drugs for preventing and treating aortic dissection. The present invention, through the study of the pharmacological effects of fibrinogen, discovered and verified the use of fibrinogen in the treatment of acute aortic dissection. Fibrinogen can reduce the breakage of elastic fibers in aortic tissue and the degradation of elastin, and maintain the contractile phenotype of VSMC, thereby effectively reducing the dissection rupture rate and the mortality rate of patients with aortic dissection. It plays a significant role in improving acute active dissection, filling the gap in drug treatment measures for acute aortic dissection.

The application belongs to the technical field of biological medicine, and particularly relates to application of calcium chelator BAPTA and a pharmaceutical composition. The calcium chelator BAPTA delays aging of lung fibroblasts and lung tissues by eliminating calcium accumulation in lung fibroblasts, reducing accumulation of reactive oxygen species ROS (ROS) in lung fibroblasts, DNA damage, and release of inflammatory factors. The calcium chelator BAPTA ultimately realizes the function of treating pulmonary fibrosis by inhibiting weight loss, lung tissue inflammatory cell infiltration, lung collagen deposition, and expression of fibrosis markers. The application provides a new drug source for delaying aging of lung fibroblasts and lung tissues and studying occurrence and development of pulmonary fibrosis. The drug is safe and reliable, has strong pharmacological action, small side effects, and definite curative effect.